Compare CLFD & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLFD | VNDA |
|---|---|---|
| Founded | 1979 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 402.8M | 361.4M |
| IPO Year | 1995 | 2005 |
| Metric | CLFD | VNDA |
|---|---|---|
| Price | $30.54 | $5.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $43.50 | $14.90 |
| AVG Volume (30 Days) | 170.0K | ★ 844.1K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $85,034,000.00 | ★ $216,105,000.00 |
| Revenue This Year | $11.64 | $21.35 |
| Revenue Next Year | $22.30 | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.51 | 8.72 |
| 52 Week Low | $23.76 | $4.14 |
| 52 Week High | $52.73 | $9.91 |
| Indicator | CLFD | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 35.18 | 30.33 |
| Support Level | $28.61 | $5.11 |
| Resistance Level | $30.99 | $5.58 |
| Average True Range (ATR) | 1.38 | 0.24 |
| MACD | -0.12 | -0.08 |
| Stochastic Oscillator | 16.35 | 0.00 |
Clearfield Inc designs, manufactures, and distributes fiber protection, fiber management, and fiber delivery solutions to enable rapid and cost-effective fiber-fed deployment throughout the broadband service provider space prominently across North America. Its 'fiber to anywhere' platform serves the requirements of Community Broadband customers, Multiple System Operators, Large Regional Service Providers, National Carriers, and International customers (including Europe, Canada, Mexico, and Caribbean Markets). Its product offerings include Accessories, Cassettes, Cable & Drop Assemblies, Frames & Panels, Microducts, Optical Components, etc. The company derives the majority of its revenue from the United States.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.